Dr. Raza Bokhari joined the board of FSD Pharma in August 2018 and was named Executive co-Chairman of the Board in December and Interim CEO in February 2019. Dr. Bokhari has been responsible for developing and leading FSD’s strategic vision into synthetic cannabinoid platforms.
Over the past two decades, Dr. Bokhari has developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. An effective “change agent,” with several years of experience and expertise in start-up and turn-around businesses, he has a history of turning around financially struggling companies. Dr. Bokhari also frequently consultants on due diligence projects for PE and VC funds focused in investing in life sciences/bio-tech and healthcare services companies.
Dr. Bokhari is also the Chairman & CEO of PCL, a global diagnostic provider of addiction screening and opioid prescription medication monitoring, including designer drugs and synthetic cannabinoids. He is also the managing partner of RBx Capital, LP and board member of Akers Biosciences (Nasdaq: AKER).
Dr. Bokhari holds a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management where he currently serves on the board. He is also the Vice Chairman of the World Affairs Council and a Trustee of the esteemed Foreign Policy Research Institute.